Research News
View articles by month and year
-
Aromasin Helps Reduce Breast Cancer Risk in High-Risk Women
Research shows that the hormonal therapy Aromasin can lower risk in high-risk, postmenopausal women who've never been diagnosed with breast cancer.
-
Zometa Plus Hormonal Therapy Reduces Recurrence Risk
A study has found that Zometa and hormonal therapy after surgery could reduce the risk of the cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer better than hormonal therapy alone.
-
Tamoxifen Effectively Lowers Breast Cancer Risk in High-Risk Women Younger Than 55
An analysis of four large studies found that tamoxifen effectively reduces breast cancer risk in women younger than 55 at high risk. This benefit outweighed the costs and potential side effects of treatment.
-
Chemo, Hormonal Therapy May Increase Risk of Falling
Research suggests that women who get chemotherapy or hormonal therapy to treat early-stage breast cancer are more likely to fall than women the same age who don't get those treatments.
-
Hormonal Therapy for Breast Cancer May Boost Lung Cancer Survival
A large study found that women treated with hormonal therapy for breast cancer were 87% less likely to die from lung cancer compared to the average person's risk of dying from lung cancer.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Results Not Clear on Whether Zometa Reduces Recurrence Risk
Two studies looking at whether Zometa could reduce the risk of early-stage breast cancer coming back (recurrence) offered conflicting results.
-
Radiation, Tamoxifen After DCIS Surgery Reduces Recurrence Risk
Research shows that radiation therapy and hormonal therapy after surgery for DCIS reduces the risk of being diagnosed with either another DCIS or invasive breast cancer in the future.
-
Experimental Osteoporosis Medicine May Reduce Breast Cancer Risk
An experimental osteoporosis medicine has been shown to reduce the risk of breast cancer in postmenopausal women.
